PAGE 5

legislation, and poli-cies. The ADA advocacy efforts are instru-mental in preventing discrimination and assuring health care coverage for those with diabetes. Importantly, the ADA is also a key advocate for increased federal diabetes research support. The ADA’s grasp of the impact of diabetes and its commitment to the vital role of research emboldens its appeals for federal re-search support (through NIH, Centers for Disease Control and Prevention, and other federal agencies) to address and reduce the public health burden of the disease.In summary, our vision—a life free of diabetes and all its burdens—may be achieved through continued dedication to support for diabetes research and active in-volvement and collaboration in the com-munity. The ADA is making progress in realizing this vision through innovative re-search, advocacy for additional research funding, and the dissemination of key research findings, all of which lead to rapid and meaningful clinical translation. While the diabetes epidemic continues to progress, the ADA recognizes the cru-cial role that research plays in slowing its momentum.The authors would like to acknowledge Megan Rowan, MPH, American Diabetes Asso-ciation, and Matt Petersen, American Diabetes Association, for their insightful comments and editorial assistance in developing the manu-script. The authors also would like to thank Alvin Powers, MD, and Elizabeth Seaquist, MD, the current and immediate past chairs of the Research Policy Committee, for their vision and leadership of the ADA research activities, and all of the past and present members of the Research Policy Committee and Research Grant Review Committee for their invaluable contributions to the research program over the years.25. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insu-lin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 2009;52:1745–175426. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer in-cidence in Scotland: a study from the Scottish Diabetes Research Network Epi-demiology Group. Diabetologia 2009;52: 1755–176527. Currie CJ, Poole CD, Gale EA. The influ-ence of glucose-lowering therapies on can-cer risk in type 2 diabetes. Diabetologia 2009;52:1766–177728. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus re-port. Diabetes Care 2010;33:1674–168529. American Diabetes Association. Standards of medical care in diabetes—2012. Diabe-tes Care 2012;35(Suppl. 1):S11–S63 30. Bang H, Edwards AM, Bomback AS, et al. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009;151:775–783care.diabetesjournals.org DIABETES CARE, VOLUME 35, JUNE 2012 1387